Under the Ryan Haight Online Pharmacy Act (2008) , prescribing controlled substances via telemedicine typically requires at least one in-person medical evaluation
The BALANCE Model Explained What lays ahead for FDA-approved weight-loss drugs and Medicare remains unclear
Ongoing support reinforces that patients dont have to manage symptoms on their own
However, it is safe to use in combination with carbidopa-levodopa formulations
The most useful conversation is not whether peptides are good or bad
For patients interested in participating in research , the following resources may be helpful: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) search for Parkinson's and GLP-1 trials Parkinson's UK (www.parkinsons.org.uk) information on current research and trial opportunities When to contact your GP or specialist : If you have Parkinson's disease and diabetes, and wish to discuss whether a GLP-1 receptor agonist is appropriate for your diabetes management If you experience new or worsening symptoms whilst taking any medication If you are interested in clinical trial participationyour neurologist can advise on suitable studies Seek urgent medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Persistent vomiting or inability to keep fluids down (risk of dehydration) Signs of dehydration (extreme thirst, dark urine, dizziness) Allergic reaction (rash, swelling, difficulty breathing) Patients should never start, stop, or modify medications without medical supervision
